Key points are not available for this paper at this time.
This study assesses mean emissions and costs and estimated total yearly emissions and costs for US-branded inhalers prescribed to Medicare Part D and Medicaid beneficiaries.
Tirumalasetty et al. (Thu,) studied this question.